Cart
sales@molnova.com
Alflutinib methanesulfonate
CAS No. 2130958-55-1
Alflutinib methanesulfonate( AST2818 | AST-2818 | ASK120067 )
Catalog No. M13393 CAS No. 2130958-55-1
Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 130 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 373 | In Stock |
|
| 50MG | 545 | In Stock |
|
| 100MG | 775 | In Stock |
|
| 200MG | 1051 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAlflutinib methanesulfonate
-
NoteResearch use only, not for human use.
-
Brief DescriptionAlflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
-
DescriptionAlflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.Lung Cancer Phase 1 Clinical(In Vitro):Alflutinib (Furmonertinib) mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation.
-
In VitroFirmonertinib mesylate can inhibit EGFR active mutations as well as the T790M acquired resistant mutation.
-
In Vivo——
-
SynonymsAST2818 | AST-2818 | ASK120067
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number2130958-55-1
-
Formula Weight664.705
-
Molecular FormulaC29H35F3N8O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 5 mg/mL 7.52 mM
-
SMILESCN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C.CS(=O)(=O)O
-
Chemical NameN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide methanesulfonate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. PCT Int. Appl. (2017), WO 2017152707 A1 20170914.
2. PCT Int. Appl. (2017), WO 2017152706 A1 20170914.
molnova catalog
related products
-
CHMFL-EGFR-202
CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).
-
AZD-3759
A potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR).
-
Poziotinib hydrochlo...
Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?
